User:Karlagay/sandbox

Cancer Genomics Consortium
The Cancer Genomics Consortium (CGC) was formed in 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who are interested in education and promoting best practices in clinical cancer genomics. The CGC has grown to an international organization with more than 400 members in more than 20 countries.

CGC members are individuals involved in the educational, medical, scientific, economic, and regulatory aspects of cancer genomics, including but not limited to clinical laboratory scientists, basic scientists, technologists, pathologists, clinicians and other health care personnel, government employees, and others are invited to participate. Education and resources are available to non-members. The CGC also provides reduced membership and annual meeting registration rates for colleagues who live or work in limited resource nations.

Since its inception in 1990, the CGC has hosted annual meetings bringing together the clinical genomics community to educate for best practices. The growth of the organization has led to numerous collaborations and publications. The CGC includes programs to boost those early in their genomics career, a webinar series, special topic working groups, and provides additional online resources to the global genomics community, including the Compendium of Cancer Genome Aberrations (CCGA).

CGC peer-reviewed publications can be found in the official journal of the organization: Cancer Genetics, published by Elsevier.

CGC Mission, Goals, and Vision
Mission Statement: The Cancer Genomics Consortium is committed to providing high quality education and promoting best laboratory practices in clinical cancer genomics.

Goals of the organization:


 * To provide expert and comprehensive knowledge of underlying genomic alterations to help manage individuals with, or at risk of, cancer
 * To provide an innovative educational forum for the better utilization of genomic technologies for clinical laboratory testing
 * To develop best practices for genomic laboratory testing in the evaluation of neoplasia
 * To generate real time curated resources for clinical genomic testing
 * To promote and facilitate multi-center genomic cancer translational research
 * To value and support the intersection of cancer and constitutional testing

Vision Statement: All cancer patients will be accurately diagnosed for their underlying genomic alterations to help them receive the most appropriate therapy. CGC will be the authoritative organization for guidance on the best practice of clinical cancer genomic testing.

CGC Collaborations
The CGC and the CCGA are listed as useful links on the WHO Classification of Tumours website.

In conjunction with VICC, CIViC, and ClinGen, the CGC produces an Unconference prior to the CGC Annual Meeting that focuses on promoting the standardization and dissemination of knowledge of the clinical significance of cancer variants.

In May 2022, the CGC Board of Directors voted to sign a letter to Senators Patty Murray and Richard Burr organized by the Association for Molecular Pathology (AMP) asking for delay of the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2022. Like many others, the CGC leadership is concerned that the VALID Act [S.2209/H.R.4128] would have significant consequences impacting delivery of laboratory-based healthcare, particularly in the development of new testing that is at the core of all we do. The letter was signed by over 70 other organizations and institutions.

CGC Publications
Pubmed ScienceDirect

Evidence-based review of genomic aberrations in diffuse large B cell lymphoma , not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group

Ashwini K.Yenamandra, Rebecca B. Smith, T. Niroshi Senaratne, Sung-Hae L. Kang, James M. Fink, Gregory Corboy, Casey A. Hodge, Xinyan Lu, Susan Mathew, Susan Crocker, Min Fang, on behalf of the Cancer Genomics Consortium Lymphoma Working Group.

Cancer Genet. 2022; 268–269:1-21. Pubmed ScienceDirect

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

Peter Horak, Malachi Griffith, Arpad M. Danos, Beth A.Pitel, Subha Madhavan, Xuelu Liu, Cynthia Chow, Heather Williams, Leigh Carmody, Lisa Barrow-Laing, Damian Rieke, Simon Kreutzfeldt, Albrecht Stenzinger, David Tamborero, Manuela Benary, Padma Sheila Rajagopal, Cristiane M. Ida, Harry Lesmana, Laveniya Satgunaseelan, Jason D. Merker, Michael Y. Tolstorukov, Paulo Vidal Campregher, Jeremy L. Warner, Shruti Rao, Maya Natesan, Haolin Shen, Jeffrey Venstrom, Somak Roy, Kayoko Tao, Rashmi Kanagal-Shamanna, Xinjie Xu, Deborah I. Ritter, Kym Pagel, Kilannin Krysiak, Adrian Dubuc, Yassmine M. Akkari, Xuan Shirley Li, Jennifer Lee, Ian King, Gordana Raca, Alex H. Wagner, Marylin M. Li, Sharon E. Plon, Shashikant Kulkarni, Obi L. Griffith, Debyani Chakravarty, Dmitriy Sonkin.

Genet Med. 2022; 24(5):986-998. Pubmed | ScienceDirect

Evidence-Based Review of Genomic Aberrations in B-Lymphoblastic Leukemia/Lymphoma: Report from the Cancer Genomics Consortium Working Group for Lymphoblastic Leukemia

Yassmine Akkari, Helene Bruyere, R. Tanner Hagelstrom, Rashmi Kanagal-Shamanna, Jie Liu, Minjie Luo, Fady M. Mikhail, Beth A. Pitel, Gordana Raca, Mary Shago, Lina Shao, Lisa R. Smith, Teresa A. Smolarek, Ashwini Yenamandra, Linda B. Baughn, on behalf of the Cancer Genomics Consortium B-ALL Working Group.

Cancer Genet. 2020; 243:52-72. Pubmed ScienceDirect

Current Concepts in Breast Cancer Genomics: An Evidence-Based Review by the CGC Breast Cancer Working Group

Katherine B. Geiersbach, Hui Chen, Rajyasree Emmadi, Gloria T. Haskell, Xinyan Lu, Yajuan J. Liu, Karen Swisshelm, on behalf of the Cancer Genomic Consortium Breast Cancer Working Group.

Cancer Genet. 2020 Jun;244:11-20. Pubmed ScienceDirect

Assessing Genome-wide Copy Number Aberrations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup

Yajuan J. Liu, Jane Houldsworth, Rajyasree Emmadi, Lisa Dyer, Daynna J. Wolff, on behalf of the Cancer Genomics Consortium Renal Neoplasia Working Group.

Cancer Genet. 2020 Jun;244:240-254 Pubmed ScienceDirect

Copy Number Assessment in the Genomic Analysis of CNS Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium (CGC) Working Group on Primary CNS Tumors

Stewart G. Neill, Jennifer Hauenstein, Marilyn M. Li, Yajuan J Liu, Minjie Luo, Debra F. Saxe, Azra H. Ligon, on behalf of the Cancer Genomics Consortium CNS Tumor Working Group.

Cancer Genet. 2020 May; 243:19-47. Pubmed ScienceDirect